Evidence map›Paper›PMID 41783430›Full record

ReviewKidney medicine2026

C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies.

Mahtab Mashayekhi, Jonathan E Zuckerman, Jonathan Barratt, Richard J Glassock, Fernando Caravaca-Fontán, Raymond K Hsu, Arun Rajasekaran, Edgar Lerma, Sahibzadi Mahrukh Noor, Amir Abdipour and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mahtab MashayekhiDivision of Nephrology, Department of Medicine, Loma Linda University Medical Center, Loma Linda, CA.
Jonathan E ZuckermanDepartment of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA.
Jonathan BarrattMayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Richard J GlassockGeffen School of Medicine at University of California at Los Angeles, Laguna Niguel, CA.
Fernando Caravaca-FontánResearch Institute "Hospital 12 de Octubre," Madrid, Spain.
Raymond K HsuDivision of Nephrology, Department of Medicine, University of California-San Francisco, San Francisco, CA.
Arun RajasekaranRenal Medicine Associates, Albuquerque, NM.
Edgar LermaDivision of Nephrology, Department of Medicine, Advocate Christ Medical Center, University of Illinois at Chicago, Oak Lawn, IL.
Sahibzadi Mahrukh NoorDivision of Nephrology, Department of Medicine, Loma Linda University Medical Center, Loma Linda, CA.
Amir AbdipourDivision of Nephrology, Department of Medicine, Loma Linda University Medical Center, Loma Linda, CA.
Sayna NorouziDivision of Nephrology, Department of Medicine, Loma Linda University Medical Center, Loma Linda, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C3 glomerulopathy (C3G) is characterized by prominent deposition of complement component C3 in the kidney glomeruli, leading to glomerular inflammation. C3G is a rare and complex pattern of injury caused by dysregulation of the alternative pathway of complement system and occurs in both children and adults. It can happen because of genetic and acquired factors. Kidney biopsy is the gold standard for diagnosing C3G. About 50% of cases progress to kidney failure, and traditional treatment strategies, including immunosuppression and supportive care, have demonstrated variable efficacy. In this review, we aim to provide a comprehensive overview of pathophysiology, clinical presentations, and diagnostic criteria of C3G. Additionally, we will discuss current treatment guidelines and ongoing clinical trials.

Indexed as

C3 glomerulonephritisC3 glomerulopathycomplement inhibitorsdense deposit disease

Identifiers

PMID41783430
PMCPMC12955118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.